Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1740

1.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

2.
3.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
4.

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Fazio S.

Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Review.

PMID:
18343268
5.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators..

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
7.

Do persons with diabetes benefit from combination statin and fibrate therapy?

Rosenblit PD.

Curr Cardiol Rep. 2012 Feb;14(1):112-24. doi: 10.1007/s11886-011-0237-7. Review.

PMID:
22213157
8.
9.

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.

Am J Cardiol. 2008 Feb 15;101(4):486-9. doi: 10.1016/j.amjcard.2007.09.095. Epub 2007 Dec 26.

PMID:
18312763
10.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
11.
12.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

13.

Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.

Jones PH.

Am J Cardiol. 2007 Feb 19;99(4A):133B-140B. Epub 2006 Dec 28. Review.

PMID:
17307065
14.

Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Brinton EA.

Curr Atheroscler Rep. 2008 Feb;10(1):25-32. Review.

PMID:
18366982
15.

Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.

Kardiol Pol. 2004 Jun;60(6):567-77. English, Polish.

PMID:
15334157
16.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
17.

Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

Saha SA, Arora RR.

Curr Opin Lipidol. 2011 Aug;22(4):270-6. doi: 10.1097/MOL.0b013e32834701c3. Review.

PMID:
21519250
19.

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.

Jones PH.

Am J Cardiol. 2008 Dec 22;102(12A):41L-47L. doi: 10.1016/j.amjcard.2008.09.074. Review.

PMID:
19084089
20.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group., Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422

Supplemental Content

Support Center